Cilostazol is an anti-platelet agent with vasodilatory activity that acts by increasing intracellular concentrations of cAMP. Recent reports have suggested that cilostazol may promote angiogenesis. In the present study, we have investigated the effect of cilostazol in promoting angiogenesis and vasculogenesis in a hindlimb ischaemia model and have also examined its potential mechanism of action in vitro and in vivo. We found that cilostazol treatment significantly increased colony formation by human early EPCs (endothelial progenitor cells) through a mechanism involving the activation of cAMP/PKA (protein kinase A), PI3K (phosphoinositide 3-kinase)/Akt/eNOS (endothelial NO synthase) and ERK (extracellular-signal-regulated kinase)/p38 MAPK (mitogenactivated protein kinase) signalling pathways. Cilostazol also enhanced proliferation, chemotaxis, NO production and vascular tube formation in HUVECs (human umbilical vein endothelial cells) through activation of multiple signalling pathways downstream of PI3K/Akt/eNOS. Cilostazol upregulated VEGF (vascular endothelial growth factor)-A 165 expression and secretion of VEGF-A in HUVECs through activation of the PI3K/Akt/eNOS pathway. In a mouse hindlimb ischaemia model, recovery of blood flow ratio (ipsilateral/contralateral) 14 days after surgery was significantly improved in cilostazol-treated mice (10 mg/kg of body weight) compared with vehicle-treated controls (0.63 + − 0.07 and 0.43 + − 0.05 respectively, P < 0.05). Circulating CD34 + cells were also increased in cilostazol-treated mice (3614 + − 670 compared with 2151 + − 608 cells/ml, P < 0.05). Expression of VEGF and phosphorylation of PI3K/Akt/eNOS and ERK/p38 MAPK in ischaemic muscles were significantly enhanced by cilostazol. Our data suggest that cilostazol produces a vasculo-angiogenic effect by up-regulating a broad signalling network that includes the ERK/p38 MAPK, VEGF-A 165 , PI3K/Akt/eNOS and cAMP/PKA pathways.
A B S T R A C T
Cilostazol is an anti-platelet agent with vasodilatory activity that acts by increasing intracellular concentrations of cAMP. Recent reports have suggested that cilostazol may promote angiogenesis. In the present study, we have investigated the effect of cilostazol in promoting angiogenesis and vasculogenesis in a hindlimb ischaemia model and have also examined its potential mechanism of action in vitro and in vivo. We found that cilostazol treatment significantly increased colony formation by human early EPCs (endothelial progenitor cells) through a mechanism involving the activation of cAMP/PKA (protein kinase A), PI3K (phosphoinositide 3-kinase)/Akt/eNOS (endothelial NO synthase) and ERK (extracellular-signal-regulated kinase)/p38 MAPK (mitogenactivated protein kinase) signalling pathways. Cilostazol also enhanced proliferation, chemotaxis, NO production and vascular tube formation in HUVECs (human umbilical vein endothelial cells) through activation of multiple signalling pathways downstream of PI3K/Akt/eNOS. Cilostazol upregulated VEGF (vascular endothelial growth factor)-A 165 expression and secretion of VEGF-A in HUVECs through activation of the PI3K/Akt/eNOS pathway. In a mouse hindlimb ischaemia model, recovery of blood flow ratio (ipsilateral/contralateral) 14 days after surgery was significantly improved in cilostazol-treated mice (10 mg/kg of body weight) compared with vehicle-treated controls (0.63 + − 0.07 and 0.43 + − 0.05 respectively, P < 0.05). Circulating CD34 + cells were also increased in cilostazol-treated mice (3614 + − 670 compared with 2151 + − 608 cells/ml, P < 0.05). Expression of VEGF and phosphorylation of PI3K/Akt/eNOS and ERK/p38 MAPK in ischaemic muscles were significantly enhanced by cilostazol. Our data suggest that cilostazol produces a vasculo-angiogenic effect by up-regulating a broad signalling network that includes the ERK/p38 MAPK, VEGF-A 165 , PI3K/Akt/eNOS and cAMP/PKA pathways.
INTRODUCTION
Blood vessel growth occurs through angiogenesis, the process by which new blood vessels are formed from pre-existing vessels, and through vasculogenesis, in which circulating progenitor cells contribute to adult neovascularization [1, 2] . Angiogenesis involves the migration and proliferation of endothelial cells, degradation of ECM (extracellular matrix) and formation of capillary tubes. A number of angiogenic factors and inhibitors that act on the vascular endothelium have been implicated in the formation of new blood vessels [2, 3] , including members of the VEGF (vascular endothelial growth factor) family [2] [3] [4] . In addition to enhancing angiogenesis, some growth factors, including VEGF and angiopoietin-1, have been reported to promote vasculogenesis in part by increasing bone-marrow-derived progenitor cell mobilization through activation of the Akt (also known as protein kinase B) signalling pathway [5, 6] .
Cilostazol {6- [4- (1-cyclohexyl-1H-tetrazol-5-yl)butoxyl]-3,4-dihydro-2-(1H)-quinolinone} is a commercially available drug that has anti-platelet and vasodilatory activity and is indicated for peripheral artery diseaserelated intermittent claudication. Cilostazol is a phosphodiesterase 3 inhibitor and mediates its effects by increasing intracellular cAMP levels [7, 8] . Interestingly, the compound has been reported to have a number of additional effects, including protection of endothelial cells from apoptosis [9, 10] , prevention of monocyte adhesion to endothelial cells [11, 12] , stimulation of the release of angiogenic factors, including VEGF and hepatocyte growth factor [13, 14] , and activation of eNOS (endothelial NO synthase) expression and NO release [15] [16] [17] [18] . Taken together, these studies suggest that cilostazol may have pro-angiogenic effects in addition to its known vasodilatory and anti-platelet functions. To the best of our knowledge, this has not yet been studied.
A substantial body of evidence has demonstrated that peripheral EPCs (endothelial progenitor cells), a fraction of bone-marrow-derived haemopoietic stem cells, play a significant role in postnatal neovascularization and vascular remodelling [19] . Circulating EPCs can be mobilized endogenously by tissue ischaemia [19] or exogenously in response to growth factors [20] [21] [22] [23] , or drugs [24, 25] through activation of Akt signalling, to travel to neovascularization sites and promote tissue repair. However, the effect of cilostazol on human early EPC function and on mobilization of bone-marrow-derived stem cells has not been reported.
The ERK (extracellular-signal-regulated kinase)/p38 MAPK (mitogen-activated protein kinase) pathway is activated by many growth factors, and may mediate endothelial cell proliferation and migration [26, 27] . Recent reports suggests that VEGF-A, especially VEGF-A 165 , is the most effective isoform in promoting angiogenesis [28] [29] [30] . However, it is not known if a relationship exists between cilostazol-induced cAMP production and ERK/p38 MAPK signalling, VEGF-A 165 expression and other angiogenesis-related signalling pathways.
In the present study, we have investigated the in vitro effect of cilostazol on angiogenesis and vasculogenesis in HUVECs (human umbilical vein endothelial cells) and human early EPCs, as well as the in vivo effect of cilostazol on murine hindlimb ischaemia. The results show that cilostazol enhances the endothelial function of human early EPCs and angiogenic capacity of HUVECs, increases VEGF-A 165 expression and VEGF-A secretion in HUVECs, and accelerates blood flow recovery and increases circulatory CD34 + cells following murine hindlimb ischaemia. These effects are shown to be mediated by up-regulation of eNOS and VEGF-A 165 , and by cross-talk between the ERK/p38 MAPK, cAMP/PKA (protein kinase A) and PI3K (phosphoinositide 3-kinase)/Akt-dependent signalling pathways.
MATERIALS AND METHODS

Reagents
Human VEGF, human bFGF (basic fibroblast growth factor), human EGF (epidermal growth factor), IGF-II (insulin-like growth factor-II), M199 medium, FBS (fetal bovine serum), Opti-MEM ® I, DAPI (4 ,6-diamidino-2-phenylindole), TRIzol ® reagent, trypsin solution and the PCR primers for VEGF-A 165 and GADPH (glyceraldehyde-3-phosphate dehydrogenase) were purchased from Invitrogen. Cilostazol, forskolin, a PKAI (PKA inhibitor), LY294002 (a PI3K inhibitor), PD98059 (an ERK MAPK inhibitor), SB203580 (a p38 MAPK inhibitor), l-NAME (N G -nitro-l-arginine methyl ester) (an eNOS inhibitor), Giemsa, Griess-Romijn, Crystal Violet reagent, DMSO, gelatin and the anti-β-actin antibody were purchased from Sigma-Aldrich. 495 ) and eNOS were from BD Transduction Laboratories. An antibody against VEGF was from Santa Cruz Biotechnology, and a BrdU (5-bromo-2-deoxyuridine) kit was purchased from Roche Diagnostic. Matrigel and a rat monoclonal antibody against murine CD31 were purchased from BD Biosciences. Biotinylated rabbit anti-rat secondary antibody, AEC (3-amino-9-ethylcarbazole) and streptavidin-HRP (horseradish peroxidase) were purchased from DAKO.
Isolation and enumeration of early EPCs
Human blood samples were obtained with informed consent from a volunteer and PBMCs (peripheral blood mononuclear cells) were isolated by Ficoll-Paque density gradient centrifugation according to standard protocols [21] . After centrifugation, cells were washed, resuspended in M199 medium supplemented with 20 % (v/v) FBS, 10 ng/ml VEGF, 2 ng/ml bFGF, 10 ng/ml EGF and 2 ng/ml IGF, and cultured in 24-well plates coated with human fibronectin. Cilostazol and inhibitors were added to the wells 3 days later. EPCs cells were confirmed by uptake of Dil-acLDL (1,1 -dioctadecyl-3,3,3 ,3 -tetramethyl-indocarbocyanine perchlorate-labelled acetylated low-density lipoprotein) and lectin as well as expression of vWF (von Willebrand factor) and VEGF-R2 (VEGF-receptor 2). Cells were harvested after 7 days, fixed and stained with Crystal Violet reagent. The colony densities were quantified with an Olympus microscope at ×100 magnification using MetaMorph imaging software (Molecular Devices).
Culture of HUVECs and cell proliferation assay
HUVECs were isolated from human umbilical cord veins as previously described [27, 31] and cultured in M199 medium supplemented with 16 % FBS. Cells from the second passage were used for all experiments. Cell proliferation was evaluated by measuring BrdU incorporation into cells, using a commercial kit according to the manufacturer's protocol. In brief, HUVECs were plated at a density of 10 4 cells/100 μl in a 96-well plate and incubated with cilostazol and inhibitors in M199 medium containing 1 % FBS for 24 h, then 100 μM of BrdU was added and the incubation was continued for a further 4 h. Absorbance was measured at a wavelength of 450 nm. The selected single dose of cilostazol was selected according to the study method as previously described [17] .
Chemotaxis assay
The chemotactic motility of HUVECs was measured using Transwells with 6.5-mm-diameter polycarbonate filters (8 μm pore size). The lower filter surface was coated with 10 μg of gelatin. Cilostazol and inhibitor solutions were placed in the lower wells, an aliquot of cell suspension (100 μl containing 10 5 cells) was placed into each upper well, and the Transwells were incubated at 37
• C for 4 h. Cells were then fixed with methanol and stained with Giemsa reagent. Cell migration was evaluated microscopically by counting the number of cells on the lower side of the filter. Five random fields in each well were counted.
Analysis of apoptotic activity
HUVECs were plated at a density of 10 4 cells/100 μl in a 96-well plate and incubated with cilostazol and inhibitors in M199 containing 1 % FBS for 24 h. To induce apoptosis, medium in each plate was removed and HUVECs were incubated in serum-free M199 for a further 24 h. Nucleosome fragmentation was assessed by ELISA using a cell death detection kit (Roche Applied Science). Experiments were performed four times.
Measurement of NO production
Supernatants were collected from HUVECs incubated with cilostazol and other reagents for 1 h. A 100 μl sample of supernatant was mixed with 10 μl of GriessRomijn reagent (100 mg/ml). Absorbance was measured at a wavelength of 540 nm.
In vitro capillary-like tube formation
Growth-factor-reduced Matrigel was thawed at 4
• C, and an aliquot of 200 μl was added to each well of a 48-well plate and polymerized for 30 min at 37
• C. Cell suspensions (200 μl) containing various concentrations of cilostazol and inhibitors were placed in the Matrigelcoated wells at 2.4×10 4 cells per well in M199 medium containing 10 % FBS, and the plates were incubated for 24 h at 37
• C in a 5% CO 2 humidified atmosphere. Images (×200 magnification) were captured with a Leica inverted microscope equipped with a Leica DC 350 FX camera, and acquired with MetaMorph software. Experiments were performed four times.
Determination of VEGF, eNOS, Akt and ERK/p38 MAPK in HUVECs
HUVECs were cultured to confluence in a 6-cmdiameter dish and incubated in M199 medium containing 1 % FBS for 18 h. Cells were washed and incubated in serum-free M199 for 6 h and treated with the indicated concentrations of cilostazol. Proteins (30 μg) from cell lysates were resolved by SDS/PAGE (8 % polyacrylamide gel) and electrophoretically blotted on to PVDF membranes (Bio-Rad Laboratories). Membranes were incubated overnight at 4
• C with specific primary antibodies against phospho-eNOS (Ser  1177 and Thr  495 ) , -eNOS, phospho-Akt (Ser 473 ), Akt, phospho-ERK (Tyr 204 ), anti-ERK, phospho-p38 MAPK (Thr 180 /Tyr 182 ) and p38 MAPK. Antibody binding was detected with HRP-conjugated secondary antibodies and enhanced chemiluminescence (PerkinElmer), and the blots were exposed to X-ray film (Fujifilm Medical).
siRNA (small interfering RNA) transfection
HUVECs (5×10 5 cells/well) were seeded into 6-cmdiameter dishes and allowed to adhere overnight. FuGENE HD reagent (Roche Applied Science) with Akt siRNA (Santa Cruz Biotechnologies) were prepared in Opti-MEM ® I, according to manufacturer's instructions. Cells were transfected with Akt siRNA and were incubated for 36 h. Negative control siRNA was also transfected. siRNA-mediated suppression of Akt expression was confirmed by Western blot analysis.
Measurement of VEGF-A 165 in HUVECs by semi-quantitative RT-PCR (reverse transcription-PCR)
Total RNA was extracted from HUVECs using TRIzol ® reagent, and 2 μg from each sample was reverse-transcribed. RT-PCR was performed using primers specific for VEGF-A 165 (5 -CCCTGGCTTTA-CTGCTGTAC-3 and 5 -TCTGAACAAGGCTCA-CAGTG-3 ) and was normalized relative to amplification of GAPDH (5 -GACCCCTTCATTGACCTC-3 and 5 -GCTAAGCAGTTGGTGGTG-3 ). PCR conditions were: activation for 3 min at 95
• C, 40 cycles of amplification for 10 s at 95
• C, 45 s at 58
• C followed by 1 min at 95
• C, 1 min at 55
• C and then 40 cycles of 10 s at 55
• C.
Measurement of VEGF-A secretion by ELISA
HUVECs (4×10 5 cells/well) were incubated for 24 h with the indicated concentrations of cilostazol in the presence or absence of inhibitors. VEGF-A secreted into the culture medium was measured using a commercial ELISA kit (R&D Systems). Assays were performed as recommended by the manufacturer and experiments were repeated three times.
Murine hindlimb ischaemia model
Eight-week-old male ICR mice were anaesthetized with an intraperitoneal injection of pentobarbital (80 mg/kg of body weight). The procedure for hindlimb ischaemia has been described previously in detail [21] . In brief, the right femoral vein was exposed and ligated. A segment from proximal end of the right femoral artery to the saphenopopliteal bifurcation, as well as the right popliteal artery, were then ligated and excised. Cilostazol was dissolved in DMSO and diluted with saline to a 20 % solution immediately before use. Cilostazol (1, 5 and 10 mg/kg of body weight) was injected intraperitoneally 30 min prior to induction of ischaemia and then twice a day at 1, 3, 10 and 30 mg/kg of body weight from days 2 to 7. Control animals received equivalent volumes of normal saline. Experimental procedures were performed according to Cheng Kung University standards for animal care.
Laser Doppler perfusion imaging
The measurement of hindlimb blood flow was performed with a LDPI (laser Doppler perfusion image) analyser (Moor Instruments), as described previously [21] . Mice were monitored by serial scanning of surface blood flow of the hindlimbs on days 3, 7, 10, 14, 21 and 28 after surgery, without influence of ambient light and temperature. The digital colour-coded images were analysed to quantify the blood flow in the region from the knee joint to the toe, and mean perfusion values were calculated. The perfusion ratio (%) was calculated as the ratio of blood flow on the ipsilateral to the contralateral side.
Quantification of CD34
+ cells by flow cytometry using the ISHAGE (International Society of Hematotherapy and Graft Engineering) protocol
We counted CD34
+ cells in peripheral blood according to the ISHAGE guidelines [32] . Briefly, 50 μl of peripheral blood was taken from the tail vein of mice and stained with phycoerythrin-conjugated anti-CD34 and FITC-conjugated anti-CD45 monoclonal antibodies (BD Pharmingen) in a TruCOUNT tube (BD Pharmingen), following the manufacturer's instructions. CD34
+ cells were then analysed and quantified on a FACSAria machine (Becton Dickinson) according to the ISHAGE sequential gating strategy.
Measurement of capillary density in ischaemic limbs
Whole limbs from experimental mice were fixed in Tissue Freezing Medium and frozen at − 80
• C. Cryostat sections (5 μm thick) were prepared and incubated with rat anti-(mouse CD31) antibody overnight at 4
• C. Sections were washed and incubated with biotinylated rabbit anti-rat secondary antibody at 1:500 dilution for 30 min. Streptavidin-HRP was added for 10 min, and colour development was performed by addition of the AEC substrate. Capillary density was quantified microscopically by counting the mean number of capillaries, as revealed by positive expression of CD31 on endothelial cells.
Western blot analysis of ischaemic muscle tissue
Homogenates of muscle tissues were prepared and proteins (40 μg per lane) were separated by SDS/PAGE (10 % polyacrylamide gel) and transferred on to PVDF membranes. Membranes were incubated with antibodies against phospho-eNOS, eNOS, phospho-Akt, Akt, phospho-ERK, ERK, phospho-p38 MAPK, p38 MAPK and VEGF. Antibody binding was detected with HRP-conjugated secondary antibodies and enhanced chemiluminescence, followed by exposure to X-ray film. The experiment was performed three times.
Statistical analysis
Results are presented as means + − S.E.M. The statistical significance of differences between the treatment groups was evaluated using ANOVA followed by Fisher's analysis for comparisons between two means. A P value of < 0.05 was considered significant. 
RESULTS
Cilostazol increases colony formation by human early EPCs
At 4 days after isolation and incubation in fibronectincoated wells, early EPCs attached and elongated into spindle shapes. A colony-forming unit was defined as a cluster with round cells in the central core and elongated sprouting cells at the periphery ( Figure 1A) . Adherent EPCs cells were confirmed by double uptake of DiIacLDL and lectin ( Figures 1B-1D ) as well as expression of vWF ( Figure 1E ) and VEGF-R2 ( Figure 1F ). Timedependent change of the colony counts from day 4 to day 7 was shown in Figure 1(G) . The addition of cilostazol to cultures stimulated EPC colony formation in a concentration-dependent manner ( Figure 1H) , with 30 μM cilostazol inducing a 2.5-fold increase in the number of colony-forming units compared with the vehicle-treated control cultures. Forskolin treatment also increased the number of EPC colony-forming units, consistent with the hypothesis that cilostazol may stimulate EPC colony formation by increasing cAMP ( Figure 1H ).
Cilostazol-simulated EPC colony formation was inhibited more effectively by ERK/p38 MAPK inhibitors than by PKAI and PI3K/eNOS inhibitors ( Figure 1H ).
Effect of cilostazol on HUVEC proliferation and migration
Cilostazol treatment enhanced HUVEC proliferation. Peak mitogenesis was observed with 30 μM cilostazol, which increased BrdU incorporation by 1.3-fold compared with that of the negative control cultures (Figure 2A ). Forskolin had a similar effect. Cilostazolstimulated HUVEC proliferation was inhibited by PKAI, l-NAME and LY294002, and a small but significant inhibitory effect was also induced by the ERK/p38 MAPK inhibitors (Figure 2A) .
HUVEC migration was also stimulated by cilostazol in a dose-dependent manner, with maximal stimulation observed at 30 μM ( Figure 2B ). The number of migrated HUVECs was 50 % greater in cultures incubated with cilostazol (30 μM) than in vehicle-treated cultures (94.76 + − 1.26 compared with 65.53 + − 0.85 cells/field, P < 0.01), and was comparable with the effect of forskolin * P < 0.05, * * P < 0.01 and * * * P < 0.001, significantly different from the vehicle control-treated cells; # P < 0.05, ## P < 0.01 and ### P < 0.001, significantly different compared with cilostazol (30 μM) treated cells.
(1 μM). PD98059 and SB203580 inhibited cilostazolstimulated HUVEC migration more effectively than did PKAI, l-NAME and LY294002 ( Figure 2B ). This result demonstrated that cilostazol promoted endothelial cell migration through multiple signalling pathways, including cAMP/PKA, PI3K/Akt/eNOS, and ERK/p38 MAPK pathways.
Cilostazol prevents apoptosis and induces NO production in HUVECs
Cilostazol reduced cell apoptosis significantly and the protective effect was reversed by treatment with PKAI, l-NAME and SB203580 ( Figure 2C ). Treatment of HUVECs with cilostazol for 1 h led also to a dosedependent increase in NO production, which attained significance at 10 and 30 μM cilostazol ( Figure 2D ).
Forskolin (1 μM) also increased NO production. The stimulatory effect of cilostazol on NO production was inhibited by incubation with PKAI, l-NAME and LY294002 ( Figure 2D ).
Cilostazol stimulates capillary-like tube formation of HUVECs on Matrigel
HUVECs cultured on Matrigel formed a capillarylike tube network ( Figure 3A) , which was denser and more mature when cells were cultured for 4 h with cilostazol ( Figure 3B ) or forskolin ( Figure 3C ) than under control conditions ( Figure 3A) . The stimulatory effect of cilostazol on capillary-like tube formation was significantly suppressed by co-incubation with PKAI ( Figure 3D ), l-NAME ( Figure 3E ), LY294002 ( Figure 3F ), PD98059 ( Figure 3G ) and SB203580 ( Figure 3H ). Measurements of capillary tube lengths revealed that the greatest stimulatory effect was seen with 30 μM cilostazol ( Figure 3I ), and this was most effectively inhibited by treatment of cells with l-NAME and LY294002. These observations suggest that cilostazol promoted capillary-like tube formation of HUVECs on Matrigel through activation of the cAMP/PKA, PI3K/Akt/eNOS and ERK/p38 MAPK signalling pathways.
Cilostazol up-regulates expression of VEGF, and phosphorylation of Akt, eNOS, ERK and p38 MAPK in HUVECs
We next analysed the expression and phosphorylation of a number of signalling molecules, as well as VEGF expression, in HUVECs treated with cilostazol and inhibitors. Our data show that cilostazol dosedependently stimulated phosphorylation of ERK, p38 MAPK, eNOS at Ser 1177 and Akt at Ser 473 , and induced dephosphorylation of eNOS at Thr 495 ( Figure 4A ). Coincubation of cells with PKAI, l-NAME and most notably with LY294002, induced a statistically significant inhibition of the cilostazol effects ( Figure 4A ; results not shown). Furthermore, the stimulatory effect of cilostazol on phosphorylation of the signalling molecules was attenuated in Akt siRNA-transfected HUVECs ( Figure 4B ). Cilostazol at 30 μM stimulated a statistically significant 2.5-fold increase in expression of VEGF-A 165 mRNA in HUVECs, as measured by semiquantitative RT-PCR ( Figure 4C ). Consistent with the mRNA results, secretion of VEGF-A protein into the culture medium was dose-dependently increased by cilostazol treatment, with a 5-fold increase being observed at the highest cilostazol concentration. As had been observed with VEGF-A mRNA, the stimulatory effect of cilostazol was blocked by co-incubation of cells with PKAI, l-NAME and LY294002 ( Figure 4D ).
Cilostazol accelerates blood flow recovery of ischaemic hindlimbs and increases circulating CD34
+ cells in vivo
Unilateral hindlimb ischaemia was induced in ICR mice. The animals were treated with vehicle or with cilostazol at 1, 5 and 10 mg/kg of body weight immediately prior to the procedure, and for 7 days thereafter (n = 12 per group). Hindlimb blood flow was monitored for up to 28 days post-surgery by laser Doppler imaging. At 14 days after surgery, blood flow in the ischaemic limbs of mice treated with cilostazol (10 mg/kg of body weight) was greater than that of animals treated with vehicle and * * P < 0.01, significantly different from the vehicle control-treated cells; # P < 0.05 and ### P < 0.001, significantly different compared with cilostazol (30 μM)-treated cells. (ratio of blood flow in ipsilateral:contralateral limbs was 0.63 + − 0.07 compared with 0.43 + − 0.05 on day 14, P < 0.005) ( Figures 5A and 5B ). Both the cilostazol-and vehicle-treated mice exhibited a time-dependent increase in the number of CD34 + cells in peripheral blood after induction of ischaemia, which reached a peak during the second week post-surgery. The number of circulating CD34 + cells was significantly higher in cilostazol-treated mice on day 14 post-surgery (3614 + − 670 compared with 2151 + − 608 cells/ml, P < 0.05) ( Figure 5C ).
Cilostazol treatment increases capillary density, expression of VEGF and phosphorylation of signalling molecules in ischaemic muscles
Immunohistochemical staining of mouse CD31 in muscle sections revealed the presence of capillary endothelial cells, and was used as a marker of capillary density ( Figure 6A ). Capillary density in the ischaemic muscles 28 days after induction of hindlimb ischaemia was significantly higher in the mice treated with cilostazol (10 mg/kg of body weight) compared with those treated with vehicle (3956 + − 111 compared with 2331 + − 66/mm 2 , P < 0.01) ( Figure 6B ). Cilostazol also increased the expression of VEGF and the phosphorylation of Akt/eNOS, ERK and p38 MAPK in ischaemic muscles in a dose-dependent manner, with maximal phosphorylation occurring at 10 mg/kg of body weight ( Figure 6C ). These effects were statistically significant (results not shown).
DISCUSSION
The results of the presetn study show for the first time that cilostazol enhances a number of pro-angiogenic functions both in vitro in cultured cells and in vivo in a mouse model of ischaemia. Cilostazol treatment increased colony formation by human early EPCs, and induced proliferation, migration, VEGF-A 165 expression and VEGF-A secretion in HUVECs. In vivo, cilostazol exhibited vasculo-angiogenic activity during murine hindlimb ischaemia by increasing the expression of VEGF-A 165 , and activating components of the eNOS, ERK/p38 MAPK, cAMP/PKA and PI3K/Akt signalling pathways. Our finding that cilostazol stimulates such diverse vasculo-angiogenic effects is novel, and may have substantial clinical implications.
The PI3K/Akt/eNOS-dependent pathway plays a pivotal role in the angiogenic properties of endothelial cells. Endothelium-derived NO is known to be a key regulator of angiogenesis [17, 18] , and it has been reported that the reciprocal phosphorylation of Ser 1177 and dephosphorylation of Thr 495 of eNOS are essential for its activation by cAMP [17, 33] . In the present study, cilostazol-induced PKA-and PI3K-dependent eNOS phosphorylation and dephosphorylation as well as NO production in HUVECs. Of note, the PKA-dependent pathway appears to play a more prominent role, consistent with a crucial role for cAMP elevation in NO regulation. Several studies [17, 34] have indicated that PI3K/Akt can modulate eNOS activity either in parallel with or downstream of cAMP/PKA signalling. However, our results suggest cilostazol has little effect on activation of PI3K/Akt through a cAMP/PKA-dependent mechanism in NO production. We speculate that a signalling pathway downstream of cAMP/PKA and distinct from PI3K/Akt may induce eNOS activation; this possibility warrants further investigation. Although cilostazol-induced proliferation and migration of HUVECs was mediated equally through activation of PKA-and PI3K-dependent pathways, the effect of cilostazol on capillary-like tube formation was mainly dependent on PI3K/Akt signalling. These findings suggest that PI3K/Akt signalling may be more important than the cAMP/PKA-dependent pathway in the angiogenic function of HUVECs. If so, this may partly explain why cilostazol is more effective in patients with intermittent claudication than is pentoxifylline, which also increases cAMP levels [13, 35] . It has been reported that p38 MAPK activation by VEGF mediates actin reorganization and cell migration in HUVECs and thus may be an important regulator of angiogenesis [26, 27] . Our data reveal that cilostazol promotes HUVEC proliferation, migration and capillary-like tube formation, which are partly mediated through the ERK/p38 MAPK signalling cascade. In this regard, cilostazol-activated ERK/p38 MAPK signalling had the greatest effect on HUVEC migration. To our knowledge, these findings have not previously been reported. Our data show that cilostazolinduced up-regulation of ERK/p38 MAPK could be partly reversed by inhibitors of PKAI, eNOS and PI3K, suggesting the possibility of cross-talk between these signalling pathways. Previous reports indicated that cAMP/PKA could either activate [36, 37] or attenuate [38] ERK MAPK signalling in several cell types, but not in vascular endothelial cells. In addition, cross-talk between the cAMP/PKA and ERK/p38 MAPK pathways has recently been identified in the regulation of placental leptin expression [39] . Our data are the first to identify such a relationship in HUVECs. cAMP may activate MAPK through members of the Ras superfamily by binding to a GEF (guanine-nucleotide-exchange factor) and activating Rap1A, which would lead to MAP phosphorylation [39, 40] .
Our results suggest that the PI3K/Akt/eNOS signalling cascade plays a pivotal role in the cilostazolinduced up-regulation of ERK/p38 MAPK in HUVECs. The pathways do not function independently, raising the possibility of additional cross-talk between these signalling modules. Previous reports indicated that eNOS could either enhance [41] or inhibit [42] MAPK expression in normal cardiomyocytes and after postmyocardial infarction, respectively. Conversely, MAPK can activate eNOS phosphorylation via oestrogen receptor α [43, 44] . To our knowledge, our study is the first to demonstrate that the ERK/p38 MAPK-dependent pathway occurs downstream of the PI3K/Akt/eNOS cascade in HUVECs.
Recently, there has been increased focus on the effects of the VEGF and the PI3K/Akt/eNOS signalling axis on the mobilization, differentiation, migration and homing of EPCs [5] . Based on the results of our study, it is reasonable to speculate that the beneficial effect of cilostazol in murine hindlimb ischaemia and regulation of circulatory stems cells could be mediated, in part, through stimulation of the PI3K/Akt/eNOS signalling pathway. However, it will also be of interest to investigate the mechanism by which the ERK and p38 MAPK inhibitors were able to inhibit cilostazolinduced colony-formation by human early EPCs. The role played by the ERK/p38 MAPK signalling cascade in the mobilization and senescence of bone-marrowderived progenitor cells has been controversial [45] [46] [47] [48] . Nevertheless, the beneficial effect of cilostazol on angiogenesis may provide further impetus to investigate the vasculo-angiogenic properties of this signalling axis.
VEGF-mediated angiogenesis is at least partially mediated by endothelial cell production of NO [49] . In addition, VEGF-induced activation of p38 MAPK has been reported to be involved in endothelial organization and formation of functional pericyte-associated vessels [30] . Recent reports suggests that VEGF-A, especially VEGF-A 165 , is the most important isoform in promoting angiogenesis [28] [29] [30] . Our present results, for the first time, provide strong evidence that cilostazol up-regulates VEGF-A 165 in HUVECs. Given that the role of VEGF in angiogenesis is well-established, the effects of cilostazol observed here have broad and important therapeutic implications for tissue protection during ischaemia.
In summary, cilostazol-induced vasculo-angiogenesis effects in vitro and in vivo are mediated through a broad signalling network that involves interplay between multiple signal transduction pathways. The results suggest that cilostazol may provide therapeutic benefit in the treatment of ischaemic disease.
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